Monatomics Technology is a development stage company pioneering a novel inhalable gas mixture, consisting of xenon, helium, oxygen, and administered by a respiratory system that reduces neurotoxicity and thereby the risk of disability in acute ischemic stroke (AIS) patients. While today's Gold Standard therapies in AIS focus on the primary injury via thrombolysis and thrombectomy (or reperfusion), Monatomics focuses on the secondary injury generated by cerebral hypoxia in the ischemic penumbra via neuroprotection. The xenon acts as a neuroprotective agent by inhibiting the NMDA glutamate receptors and blocking the cascade of excitotoxicity. Monatomics' unique proprietary respiratory system recycles the xenon gas (thus making the solution commercially viable) and is scalable as it can be operated by any medical professional at any care setting - a significant hurdle in today's stroke reperfusion therapies.